Literature DB >> 32147744

Legius Syndrome and its Relationship with Neurofibromatosis Type 1.

Ellen Denayer, Eric Legius.   

Abstract

Neurofibromatosis type 1 (NF1) is the most common disorder characterized by multiple café-au-lait macules. Most individuals with this autosomal dominant disorder also have other features, such as skinfold freckling, iris Lisch nodules and benign or malignant peripheral nerve sheath tumours. Legius syndrome is a less frequent autosomal dominant disorder with similar multiple café-au-lait macules and skinfold freckling. Legius syndrome is not characterized by an increased risk of tumours, and a correct diagnosis is important. In young children with a sporadic form of multiple café-au-lait macules with or without freckling and no other manifestations of NF1 these 2 conditions cannot be differentiated based on clinical examination. Molecular analysis of the NF1 and SPRED1 genes is usually needed to differentiate the 2 conditions. Other less frequent conditions with café-au-lait macules are Noonan syndrome with multiple lentigines, constitutional mismatch repair deficiency and McCune-Albright syndrome.

Entities:  

Keywords:  Legius syndrome; NF1; SPRED1; CAL

Mesh:

Substances:

Year:  2020        PMID: 32147744      PMCID: PMC9128993          DOI: 10.2340/00015555-3429

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   3.875


  43 in total

1.  SPRED1 disorder and predisposition to leukemia in children.

Authors:  Eric Pasmant; Paola Ballerini; Helene Lapillonne; Christine Perot; Dominique Vidaud; Guy Leverger; Judith Landman-Parker
Journal:  Blood       Date:  2009-07-30       Impact factor: 22.113

2.  Loss of NF1 allele in Schwann cells but not in fibroblasts derived from an NF1-associated neurofibroma.

Authors:  L Kluwe; R Friedrich; V F Mautner
Journal:  Genes Chromosomes Cancer       Date:  1999-03       Impact factor: 5.006

3.  Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium.

Authors:  Doua Bakry; Melyssa Aronson; Carol Durno; Hala Rimawi; Roula Farah; Qasim Kholaif Alharbi; Musa Alharbi; Ashraf Shamvil; Shay Ben-Shachar; Matthew Mistry; Shlomi Constantini; Rina Dvir; Ibrahim Qaddoumi; Steven Gallinger; Jordan Lerner-Ellis; Aaron Pollett; Derek Stephens; Steve Kelies; Elizabeth Chao; David Malkin; Eric Bouffet; Cynthia Hawkins; Uri Tabori
Journal:  Eur J Cancer       Date:  2014-01-15       Impact factor: 9.162

4.  Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients.

Authors:  M Ruggieri; P Iannetti; A Polizzi; I La Mantia; A Spalice; O Giliberto; N Platania; A L Gabriele; V Albanese; L Pavone
Journal:  Neuropediatrics       Date:  2005-02       Impact factor: 1.947

5.  SPRED 1 mutations in a neurofibromatosis clinic.

Authors:  Talia M Muram-Zborovski; David A Stevenson; David H Viskochil; David C Dries; Andrew R Wilson
Journal:  J Child Neurol       Date:  2010-02-22       Impact factor: 1.987

6.  A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1.

Authors:  Irma B Stowe; Ellen L Mercado; Timothy R Stowe; Erika L Bell; Juan A Oses-Prieto; Hilda Hernández; Alma L Burlingame; Frank McCormick
Journal:  Genes Dev       Date:  2012-07-01       Impact factor: 11.361

7.  An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation.

Authors:  M Upadhyaya; S M Huson; M Davies; N Thomas; N Chuzhanova; S Giovannini; D G Evans; E Howard; B Kerr; S Griffiths; C Consoli; L Side; D Adams; M Pierpont; R Hachen; A Barnicoat; H Li; P Wallace; J P Van Biervliet; D Stevenson; D Viskochil; D Baralle; E Haan; V Riccardi; P Turnpenny; C Lazaro; L Messiaen
Journal:  Am J Hum Genet       Date:  2006-12-08       Impact factor: 11.025

8.  Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis.

Authors:  E Legius; D A Marchuk; F S Collins; T W Glover
Journal:  Nat Genet       Date:  1993-02       Impact factor: 38.330

Review 9.  What's new in the neuro-cardio-facial-cutaneous syndromes?

Authors:  Ellen Denayer; Eric Legius
Journal:  Eur J Pediatr       Date:  2007-07-05       Impact factor: 3.183

10.  SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype.

Authors:  E Pasmant; A Sabbagh; N Hanna; J Masliah-Planchon; E Jolly; P Goussard; P Ballerini; F Cartault; S Barbarot; J Landman-Parker; N Soufir; B Parfait; M Vidaud; P Wolkenstein; D Vidaud; R N F France
Journal:  J Med Genet       Date:  2009-04-14       Impact factor: 6.318

View more
  4 in total

1.  Application of Combined Long Amplicon Sequencing (CoLAS) for Genetic Analysis of Neurofibromatosis Type 1: A Pilot Study.

Authors:  Sumihito Togi; Hiroki Ura; Yo Niida
Journal:  Curr Issues Mol Biol       Date:  2021-07-23       Impact factor: 2.976

2.  Central precocious puberty in a girl with LEGIUS syndrome: an accidental association?

Authors:  Valentina Orlandi; Paolo Cavarzere; Laura Palma; Rossella Gaudino; Franco Antoniazzi
Journal:  Ital J Pediatr       Date:  2021-03-04       Impact factor: 2.638

Review 3.  Challenges in the diagnosis of neurofibromatosis type 1 (NF1) in young children facilitated by means of revised diagnostic criteria including genetic testing for pathogenic NF1 gene variants.

Authors:  Hildegard Kehrer-Sawatzki; David N Cooper
Journal:  Hum Genet       Date:  2021-12-20       Impact factor: 4.132

Review 4.  Cutaneous Expression of Familial Cancer Syndromes.

Authors:  Anne-Johanne Andersen; Juliane Schierbeck; Anette Bygum; Nieves Puente-Pablo
Journal:  Acta Derm Venereol       Date:  2021-07-30       Impact factor: 3.875

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.